Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.34
IMMU's Cash to Debt is ranked lower than
89% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. IMMU: 0.34 )
Ranked among companies with meaningful Cash to Debt only.
IMMU' s Cash to Debt Range Over the Past 10 Years
Min: 0.26  Med: No Debt Max: No Debt
Current: 0.34
Equity to Asset -1.78
IMMU's Equity to Asset is ranked lower than
98% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IMMU: -1.78 )
Ranked among companies with meaningful Equity to Asset only.
IMMU' s Equity to Asset Range Over the Past 10 Years
Min: -1.78  Med: 0.72 Max: 0.92
Current: -1.78
-1.78
0.92
F-Score: 2
Z-Score: -15.38
M-Score: -2.86
WACC vs ROIC
15.71%
-550.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1844.85
IMMU's Operating margin (%) is ranked lower than
83% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. IMMU: -1844.85 )
Ranked among companies with meaningful Operating margin (%) only.
IMMU' s Operating margin (%) Range Over the Past 10 Years
Min: -1844.85  Med: -289.05 Max: 55.69
Current: -1844.85
-1844.85
55.69
Net-margin (%) -1844.67
IMMU's Net-margin (%) is ranked lower than
83% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. IMMU: -1844.67 )
Ranked among companies with meaningful Net-margin (%) only.
IMMU' s Net-margin (%) Range Over the Past 10 Years
Min: -1844.67  Med: -212.6 Max: 60.72
Current: -1844.67
-1844.67
60.72
ROA (%) -88.27
IMMU's ROA (%) is ranked lower than
83% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. IMMU: -88.27 )
Ranked among companies with meaningful ROA (%) only.
IMMU' s ROA (%) Range Over the Past 10 Years
Min: -88.27  Med: -32.8 Max: 74.44
Current: -88.27
-88.27
74.44
ROC (Joel Greenblatt) (%) -292.53
IMMU's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. IMMU: -292.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IMMU' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2222.63  Med: -265.32 Max: 760.43
Current: -292.53
-2222.63
760.43
Revenue Growth (3Y)(%) -19.00
IMMU's Revenue Growth (3Y)(%) is ranked lower than
73% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. IMMU: -19.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IMMU' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.9  Med: 2.9 Max: 81.6
Current: -19
-56.9
81.6
EBITDA Growth (3Y)(%) 66.30
IMMU's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. IMMU: 66.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IMMU' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.2  Med: -7.4 Max: 66.3
Current: 66.3
-26.2
66.3
EPS Growth (3Y)(%) 60.50
IMMU's EPS Growth (3Y)(%) is ranked higher than
94% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. IMMU: 60.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IMMU' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.3  Med: -12.6 Max: 84.2
Current: 60.5
-36.3
84.2
» IMMU's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-08-17)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

IMMU Guru Trades in Q2 2015

Paul Tudor Jones 17,600 sh (New)
» More
Q3 2015

IMMU Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q2 2016

IMMU Guru Trades in Q2 2016

Jim Simons 1,772,807 sh (New)
» More
Q3 2016

IMMU Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IMMU

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:EDGE, NAS:VYGR, AMEX:BTX, NAS:NLNK, NAS:BSTC, NAS:LJPC, NAS:NDRM, NAS:ADXS, NAS:OMED, NAS:NVAX, NAS:GERN, NAS:ADAP, NAS:SVA, NAS:SPPI, NAS:AKBA, NAS:SRNE, NAS:CRBP, NAS:CCXI, NAS:ARNA, NAS:CEMP » details
Traded in other countries:IM3.Germany,
Immunomedics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Immunomedics Inc was incorporated in Delaware in 1982. It is a biopharmaceutical company, which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or 'naked' form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes two antibody-drug conjugates sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). DNL is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all autoimmune disease indications. It manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Its geographic locations include United States and Europe. It competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, ImmunoGen Merck Serono, Genmab, Celgene, Amgen, Bristol-Myers Squibb, Bayer Healthcare Pharmaceuticals, Pfizer, AstraZeneca and Eli Lilly, are engaged in the development of therapeutic autoimmune and oncology products. Its patents include approximately 267 active patents in the U.S. and more than 400 other issued patents all over the world. Its research and development activities, including testing in laboratory animals and in humans, its manufacture of antibodies, as well as the handling, labeling and storage of the product candidates that the company is developing, are all subject to stringent regulation, by the FDA in the U.S. and by comparable authorities in other countries.

Ratios

vs
industry
vs
history
P/S 108.82
IMMU's P/S is ranked lower than
85% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. IMMU: 108.82 )
Ranked among companies with meaningful P/S only.
IMMU' s P/S Range Over the Past 10 Years
Min: 2.96  Med: 29.88 Max: 132.94
Current: 108.82
2.96
132.94
EV-to-EBIT -7.68
IMMU's EV-to-EBIT is ranked lower than
99.99% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. IMMU: -7.68 )
Ranked among companies with meaningful EV-to-EBIT only.
IMMU' s EV-to-EBIT Range Over the Past 10 Years
Min: -343.7  Med: -6.9 Max: 298.3
Current: -7.68
-343.7
298.3
EV-to-EBITDA -7.77
IMMU's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. IMMU: -7.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMMU' s EV-to-EBITDA Range Over the Past 10 Years
Min: -226.2  Med: -7.2 Max: 393.3
Current: -7.77
-226.2
393.3
Current Ratio 2.52
IMMU's Current Ratio is ranked lower than
68% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. IMMU: 2.52 )
Ranked among companies with meaningful Current Ratio only.
IMMU' s Current Ratio Range Over the Past 10 Years
Min: 0.6  Med: 4.13 Max: 12.5
Current: 2.52
0.6
12.5
Quick Ratio 2.50
IMMU's Quick Ratio is ranked lower than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. IMMU: 2.50 )
Ranked among companies with meaningful Quick Ratio only.
IMMU' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 4.06 Max: 12.23
Current: 2.5
0.59
12.23
Days Inventory 101.19
IMMU's Days Inventory is ranked higher than
61% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. IMMU: 101.19 )
Ranked among companies with meaningful Days Inventory only.
IMMU' s Days Inventory Range Over the Past 10 Years
Min: 101.19  Med: 310.77 Max: 938.67
Current: 101.19
101.19
938.67
Days Sales Outstanding 65.71
IMMU's Days Sales Outstanding is ranked lower than
54% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. IMMU: 65.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMMU' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.57  Med: 24.8 Max: 105.77
Current: 65.71
2.57
105.77
Days Payable 1.00
IMMU's Days Payable is ranked lower than
96% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. IMMU: 1.00 )
Ranked among companies with meaningful Days Payable only.
IMMU' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 1684.86 Max: 4523.25
Current: 1
1
4523.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
IMMU's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. IMMU: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMMU' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.6  Med: -5 Max: -0.1
Current: -5
-14.6
-0.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.63
IMMU's Price/Median PS Value is ranked lower than
91% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. IMMU: 3.63 )
Ranked among companies with meaningful Price/Median PS Value only.
IMMU' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 1.08 Max: 7.25
Current: 3.63
0.11
7.25
Earnings Yield (Greenblatt) (%) -13.05
IMMU's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. IMMU: -13.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IMMU' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.5  Med: 5 Max: 18.5
Current: -13.05
-13.5
18.5

More Statistics

Revenue (TTM) (Mil) $3.24
EPS (TTM) $ -0.63
Beta2.40
Short Percentage of Float19.35%
52-Week Range $1.61 - 5.44
Shares Outstanding (Mil)105.94
» More Articles for IMMU

Headlines

Articles On GuruFocus.com
Immunomedics Inc. Reports Operating Results (10-Q) Feb 04 2011 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Immunomedics Inc. Reports Operating Results (10-K) Aug 26 2010 
Fastest Growing Magic Formula Stocks: Jiangbo Pharmaceuticals, DragonWave, Immunomedics, Genoptix, P Jul 15 2010 
Immunomedics Inc. Reports Operating Results (10-Q) May 10 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 02 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Immunomedics Inc. Reports Operating Results (10-K) Aug 27 2009 
Immunomedics Inc. Reports Operating Results (10-Q) May 11 2009 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Does Immunomedics, Inc. (IMMU)’s New Candidate IMMU-140 Stand A Chance Of Success? Dec 07 2016
Immunomedics Introduces New Antibody-Drug Conjugate at Annual Meeting of American Society of... Dec 06 2016
Immunomedics, Inc. (IMMU): The Smart Money Is Quietly Loading Up On This Stock Dec 02 2016
venBio Responds to Immunomedics’ Postponement of Annual Meeting Nov 29 2016
IMMUNOMEDICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Nov 28 2016
Immunomedics Postpones 2016 Annual Meeting of Stockholders Nov 28 2016
venBio Comments on its Recent Nomination of Four Highly-Qualified Candidates for Board of... Nov 22 2016
Immunomedics Comments on Receipt of Director Nominations Nov 18 2016
IMMUNOMEDICS EXPANDS ANTIBODY-DRUG CONJUGATE PROGRAM TO POTENTIALLY ADDRESS MOST OF HUMAN CANCERS Nov 15 2016
Immunomedics Expands Antibody-Drug Conjugate Program to Potentially Address Most of Human Cancers Nov 15 2016
Immunomedics to Provide Clinical Update on Sacituzumab Govitecan (IMMU-132) in Triple-Negative... Nov 14 2016
IMMUNOMEDICS INC Financials Nov 09 2016
ETF’s with exposure to Immunomedics, Inc. : November 8, 2016 Nov 08 2016
Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2017 By the Numbers : November 7, 2016 Nov 07 2016
IMMUNOMEDICS RECEIVES EDISON PATENT AWARD FROM RESEARCH & DEVELOPMENT COUNCIL OF NEW JERSEY FOR THE... Nov 04 2016
Immunomedics Receives Edison Patent Award From Research & Development Council of New Jersey for the... Nov 04 2016
Edited Transcript of IMMU earnings conference call or presentation 2-Nov-16 9:00pm GMT Nov 03 2016
Blog Coverage Celldex Acquires Cancer Medicine Company for $62.5 Million Nov 03 2016
Immunomedics reports 1Q loss Nov 02 2016
Immunomedics reports 1Q loss Nov 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)